{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": {
    "pdf_name": "Zimmerman_et_al.__2023_",
    "source_pdf": "data/clinical_files/Zimmerman et al. (2023).pdf",
    "total_pages": 7,
    "total_blocks": 97,
    "total_characters": 22898
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "RIV4 was Flublok.",
      "relevance_explanation": "This quote explicitly identifies Flublok as the recombinant quadrivalent influenza vaccine (RIV4) evaluated in the study, establishing the product under discussion."
    },
    {
      "id": 2,
      "quote": "because it is not subject to mutations to the A (H3N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "relevance_explanation": "This statement directly supports the claim by indicating that Flublok (RIV4), unlike egg-based vaccines, is not affected by mutations that can occur during egg-based manufacturing, which can alter the antigenic match to WHO- and FDA-selected flu strains."
    }
  ],
  "model_used": "gpt-4.1"
}